Skip to content

BIO FRONTIER

  • Home
  • Artificial intelligence
  • Biotechnology
  • Genetics
  • Medical Technology

Edmund Ingham

    • Home
    • Edmund Ingham
Biotechnology Edmund Ingham SPRY Uncategorized

ARS Pharmaceuticals: Neffy’s Slow Launch, No Guidance For 2026 Keep Me On Sidelines

Mar 11, 2026
Biotechnology CRSP Edmund Ingham NTLA Uncategorized VRTX

Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here’s My Take

Mar 9, 2026
Biotechnology Edmund Ingham Uncategorized XENE

Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked

Mar 9, 2026
Biotechnology Edmund Ingham TNGX Uncategorized

Tango Therapeutics: I’m Not Buying Into Latest Rally, Despite PRMT5 Promise

Mar 6, 2026
Biotechnology Edmund Ingham PEPG SRPT Uncategorized

PepGen: Stock Slides On FDA Study Hold – I’m Firmly On The Sidelines

Mar 5, 2026
Biotechnology Edmund Ingham SLS Uncategorized

Sellas Life Sciences: REGAL Study Results Due Any Day Are A Major Potential Upside Catalyst

Mar 5, 2026
Biotechnology COGT Edmund Ingham Uncategorized

Cogent Biosciences: Trio Of Approvals Beckon For Lead Drug – Still Bullish

Mar 4, 2026
Biotechnology Edmund Ingham IOVA Uncategorized

Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain – I’m Still Bullish After All These Years

Mar 4, 2026
Biotechnology Edmund Ingham QURE Uncategorized

uniQure: Shares Tumble On Fresh FDA Controversy – What Investors Should Know

Feb 27, 2026
Biotechnology Edmund Ingham RXRX Uncategorized

Recursion Pharmaceuticals Q4: Why My December Buy Call Was Too Optimistic

Feb 25, 2026
Next Page »
  • PR Newswire
  • GlobeNewswire
  • Contact
  • Privacy Policy

BIO FRONTIER

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.